Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

ANASA (Patients' Satisfaction With Pulmonary Diseases' Treatment)

This study has been completed.
Information provided by (Responsible Party):
Elpen Pharmaceutical Co. Inc. Identifier:
First received: October 12, 2011
Last updated: November 18, 2011
Last verified: November 2011

The aim of the study is to compare patients' satisfaction from the use of three different inhalation devices by using the FSI-10 questionnaire

Chronic Obstructive Pulmonary Disease

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Multicenter, Prospective, Non Interventional Observational Study in Treatments of Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Resource links provided by NLM:

Further study details as provided by Elpen Pharmaceutical Co. Inc.:

Primary Outcome Measures:
  • Patients' satisfaction [ Time Frame: all study period (5 months) ] [ Designated as safety issue: No ]
    Patients' replies to FSI-10 questionnaire valid in Greek language

Secondary Outcome Measures:
  • Patients devices' use [ Time Frame: all study period (5 months) ] [ Designated as safety issue: No ]

Enrollment: 1160
Study Start Date: January 2011
Study Completion Date: September 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Turbuhaler inhaler use
Discus inhaler use
Elpenhaler inhaler use

Detailed Description:

Patients are requested to reply to FSI-10 questionnaire regarding their satisfaction from inhalation devices. Patients are on 3 different asthma inhalation devices with combination treatment (Turbuhaler, Diskus, Elpenhaler)


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Three subgroups of patients who are already in their inhalation treatment (devices: Discus, Elpenhaler, Turbuhaler) are asked to complete the FSI-10 questionnaire valid in Greek language. The questionnaire responses indicate their satisfaction by their treatment devices.


Inclusion Criteria:

  • Patients > 18 years old, both genders who are on their inhalation treatment at least two months before study enrollment,
  • Who are able to be compliant to study procedures

Exclusion Criteria:

  • Patients < 18 years old,
  • Patients who are on their inhalation treatment less than two months before study enrollment
  • Patients who are not able to be compliant to study procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01475045

7th Pulmonary Clinic, Sotiria Hospital
Athens, Greece
Sotiria Hospital
Athens, Greece
Sponsors and Collaborators
Elpen Pharmaceutical Co. Inc.
Principal Investigator: Asimina Gaga 7th Pulmonary Clinic, Sotiria Hospital of Athens
  More Information

Additional Information:
No publications provided

Responsible Party: Elpen Pharmaceutical Co. Inc. Identifier: NCT01475045     History of Changes
Other Study ID Numbers: 20109-HAL-EL-02, Sponsor ID
Study First Received: October 12, 2011
Last Updated: November 18, 2011
Health Authority: Greece: National Organization of Medicines

Keywords provided by Elpen Pharmaceutical Co. Inc.:

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Bronchial Diseases
Hypersensitivity, Immediate
Immune System Diseases
Respiratory Hypersensitivity
Respiratory Tract Diseases processed this record on February 26, 2015